Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.
Healthcare technology companies can now use AFib findings recorded by an Apple Watch to help demonstrate the effectiveness of their devices to the FDA.
Sunil Rao, MD, director of interventional cardiology at NYU Langone, says DanGer Shock is a "very, very important study" when it comes to the treatment of cardiogenic shock.
Two-year outcomes of a QFR-guided vessel and lesion selection strategy showed that the benefits of QFR guidance continued to accrue over time compared with standard angiography guidance in patients undergoing PCI.
New data on the Medtronic Intrepid transcatheter mitral valve replacement system from the Intrepid Pilot Study and Intermediate-Term Outcomes of the Intrepid Early Feasibility Study, were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Two late-breaking studies at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) meeting provided positive data for Abbott's MitraClip transcatheter mitral valve repair (TMVR) device and the TriClip for transcatheter tricuspid valve repair (TTVR).
Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.
The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications.
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."